StockData

Ametek vs Sensata Technologies

AME and ST side by side, both in laboratory apparatus and analytical, optical, measuring, and controlling instruments. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AME and ST compare

Ametek is the larger company, worth 9.4 times as much as Sensata Technologies ($55.3B against $5.9B).

On earnings, Ametek is cheaper: it trades at 35.3× trailing earnings, against 67.1× for Sensata Technologies.

Ametek grew revenue faster over the last twelve months (12.7% versus 0.80% for Sensata Technologies).

Ametek keeps more of each dollar of sales as profit, with a net margin of 20.0% compared with 2.4% at Sensata Technologies.

Both pay dividends: Ametek yields 0.55% and Sensata Technologies 1.2%.

Ametek scores higher on the StockData Score (18 against 11 for Sensata Technologies), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAMEST
Size and price
Market cap$55.3B$5.9B
Share price$241.12$40.27
Change, 1 year30.9%23.4%
Change, 5 years71.1%−32.6%
Beta (5Y)0.891.21
Employees13K21K
StockData Score
Total score18 (better)11
Valuation score12 (better)
Growth score3 (better)1
Performance score5 (better)2
Health score6 (better)3
Dividend score33
Valuation
P/E35.3× (better)67.1×
P/S7.0×1.6× (better)
P/B4.9×2.0× (better)
EV/EBITDA23.1×15.1× (better)
P/FCF30.3×10.1× (better)
PEG4.15–
FCF yield3.3%9.9% (better)
Fair value$207.73$37.27
Margin of safety−16.1%−8.1% (better)
Growth
Revenue growth (TTM)12.7% (better)0.80%
Revenue growth, 5Y average10.3% (better)4.0%
Net income growth (TTM)9.6% (better)−19.3%
EPS growth (TTM)10.1% (better)−20.0%
EPS growth, 5Y average11.2% (better)−27.4%
Profitability
Gross margin36.4% (better)29.5%
Operating margin25.9% (better)7.5%
Net margin20.0% (better)2.4%
FCF margin23.2% (better)15.3%
Return on equity14.6% (better)3.1%
Return on invested capital13.7% (better)2.8%
Financial health
Debt / equity0.18 (better)0.82
Net debt / EBITDA0.63 (better)3.86
Interest coverage21.1× (better)2.0×
Current ratio1.212.29 (better)
Altman Z-score8.23 (better)2.40
Piotroski F-score8 (better)6
Dividends and buybacks
Dividend yield0.55%1.2% (better)
Payout ratio18.9%77.8%
Buyback yield0.80% (better)0.43%
Shareholder yield1.4%1.6% (better)
Ownership
Held by institutions89.7%106%
Held by insiders0.37%1.0%
Insider net buying, 12 months−$28.5M−$8.0M (better)
Superinvestors holding1–
Short interest, % of float1.7%5.1%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.